Future research focusing on the crosstalk between the PI3K/AKT/mTOR signaling axis and the cellular metabolism in HCC may help to reveal the impact of metabolic reprogramming in cancer cells and contribute to the development of novel potential therapeutic agents. This evidence concerns the gene PIK3CD and hepatocellular carcinoma.